en · de · es · fr · pt
cjc-1295-notes.peptides9002.com › Topic › Background And Naming Conventions — Quick Reference

Background And Naming Conventions — Quick Reference

By Editorial Desk · published 2025-12-04 · last reviewed 2026-01-22 · Topic

Everything below concerns Drug affinity complex. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-01-22. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Naming Conventions

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

Background and Receptor Mechanism

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

Cjc-1295 at a glance

PropertyValueNotes
Molecular classSynthetic peptideAnalog of growth hormone-releasing hormone
Chain length29 amino acidsBased on the GRF(1-29) fragment
AppearanceWhite to off-white lyophilized powderCommon research supply form
SolubilitySoluble in water and aqueous buffersPowder requires reconstitution before use
Typical storage−20 °C or belowKept away from light and moisture

Persistence, Stability and Measurement

Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Related pages on this site

CJC-1295 Structure And Mechanism

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

Identity and Naming History

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Background from the literature

Abu Omar al-Shishani Abu Sayfullah Shishani Abu Said Shishani Ahmad Shishani Abu Abdullah Shishani Al Bara Shishani Abu Ibrahim Shishani Abu Umar Grozny Musa Abu Yusuf Shishani Hayrullah Shishani Abdullah Shishani Abu Hafs Shishani Adam Shishani Abdul-Halim Shishani Hattab Shishani Abdullah Abu Muhammad Shishani Abdul-Vahhab Shishani Muhammad Shishani Abu Hisham Shishani Abu Anas Shishani Abu Shamil Shishani Jundullah Shishani

Oxytocin stimulates powerful uterine contractions, which trigger labour and delivery of an infant, and milk ejection in nursing women. Its release is mediated reflexively by the hypothalamus and represents a positive feedback mechanism. Antidiuretic hormone stimulates the kidney tubules to reabsorb and conserve water, resulting in small volumes of highly concentrated urine and decreased plasma osmolality. Antidiuretic hormone is released in response to high solute concentrations in the blood and inhibited by low solute concentrations in the blood. Hyposecretion results in diabetes insipidus.

==== Fungal origin ==== Sometimes fungal infections occur on the gums. Candida species such as C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondiiare the most common fungi capable of causing gingival lesions. Linear gingival erythema is classified as a candida-associated lesion, that is to say Candida species are involved, and in some cases the lesion responds to antifungal therapy, but it is thought that other factors exist, such as oral hygiene and human herpesviruses. Linear gingival erythema presents as a localized or generalized, linear band of erythematous (red) gingivitis. It was first observed in HIV infected individuals and termed "HIV-gingivitis", but the condition is not confined to this group. This condition can develop into necrotizing ulcerative periodontitis. Histoplasma capsulatum is the causative organism in histoplasmosis, which may occasionally involve the gums.

Samberg starred in Sleater-Kinney's "No Cities to Love" video along with other actors such as Fred Armisen, Elliot Page, and Norman Reedus. On May 16, 2016, Samberg and the Lonely Island performed their 2009 hit "I'm on a Boat" with classroom instruments on The Tonight Show Starring Jimmy Fallon, as part of a recurring segment on the show.

== Personal life == In 2002, at the age of 19, she gave birth to her son, whom she had with the musician Thomas-John Mitchell. Marlowe is named after Christopher Marlowe. She gave birth to another boy in 2022, whose father is the illustrator Stéphane Manel.

Sources: en.wikipedia.org

Further detail

The European Food Safety Authority (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL are defined the same as in the United States. For women and men of ages 15 and older, the PRIs are set respectively at 650 and 750 μg RE/day. PRI for pregnancy is 700 μg RE/day, for lactation 1300/day. For children of ages 1–14 years, the PRIs increase with age from 250 to 600 μg RE/day. These PRIs are similar to the US RDAs. The EFSA reviewed the same safety question as the United States, and set ULs at 800 for ages 1–3, 1100 for ages 4–6, 1500 for ages 7–10, 2000 for ages 11–14, 2600 for ages 15–17 and 3000 μg/day for ages 18 and older for preformed vitamin A, i.e., not including dietary contributions from carotenoids.

==== Oral appliances ==== An oral appliance, often referred to as a mandibular advancement splint, is a custom-made mouthpiece that shifts the lower jaw forward and opens the bite slightly, opening up the airway. These devices can be fabricated by a general dentist. Oral appliance therapy is usually successful in patients with mild to moderate obstructive sleep apnea. While CPAP is more effective for sleep apnea than oral appliances, oral appliances improve sleepiness and quality of life and are often better tolerated than CPAP. A novel oral device, the C.A.R.E. device (DNA, mRNA and mmRNA), has a dual action of both holding the lower jaw (mandible) forward to open the airway while sleeping and developing the volume of the upper jaw bone (maxilla) improving nasal volume. Many dental appliances can expand the maxilla and increase the nasal airway volume as measured by CBCT and acoustic rhinometry but the novel C.A.R.E. device (DNA, mRNA and mmRNA) has a protocol for wear time and adjustment that is different than these devices. This has resulted in the safe and effective resolution of sleep apnea in children and adults. The CARE device (DNA, mRNA and mmRNA) and protocol was FDA cleared for snoring and for obstructive sleep apnea in 2023. Larger studies are needed. Cross-functional team research is needed to specifically determine the impact of oral devices and their materials that i.e. might stimulate osteogenesis potentially changing the size and shape of a bone (the maxilla).

A pulmonary embolism is a blood clot that becomes lodged in the pulmonary arteries. The majority of emboli arise because of deep vein thrombosis in the legs. Pulmonary emboli may be investigated using a ventilation/perfusion scan, a CT scan of the arteries of the lung, or blood tests such as the D-dimer. Pulmonary hypertension describes an increased pressure at the beginning of the pulmonary artery that has a large number of differing causes. Other rarer conditions may also affect the blood supply of the lung, such as granulomatosis with polyangiitis, which causes inflammation of the small blood vessels of the lungs and kidneys. A lung contusion is a bruise caused by chest trauma. It results in hemorrhage of the alveoli causing a build-up of fluid which can impair breathing, and this can be either mild or severe. The function of the lungs can also be affected by compression from fluid in the pleural cavity pleural effusion, or other substances such as air (pneumothorax), blood (hemothorax), or rarer causes. These may be investigated using a chest X-ray or CT scan, and may require the insertion of a surgical drain until the underlying cause is identified and treated.

=== Gene === The human LECT2 gene, LECT2, is located on the long, i.e., "q", arm of chromosome 5 at position q31.1 (notated as 5q31.1). This location is close to several immune modulating genes including interleukins 3, 5, and 9 and granulocyte-macrophage colony stimulating factor. LECT2 is conserved in zebrafish, chicken, rat, mouse, cow. dog, Rhesus monkey, and chimpanzee. Human LECT2 is composed of 4 exons, 3 introns, and ~8,000 base pairs. The gene has numerous single nucleotide variants as well as other variations, two of which (see Pathophysiology section) have been associated with human disease. Human LECT2 has several different transcriptional initiation sights and codes for a mRNA composed of 1,000 to 1,300 ribonucleotides. mRNA for LECT2 is highly expressed in liver tissue and expressed at far lower levels in a wide range of other tssues.

A compromise solution was worked out whereas the infantry would attack north from both sides of Lake Ilmen, while the panzer group would advance from its current position. Hoepner's forces began their advance on August 8, but the attack ran into determined Soviet defences. Elsewhere, Soviet counter-attacks threatened Leeb's southern flank. By mid to late August, the German forces were making gains again, with the 4th Panzer Group taking Narva on 17 August. On 29 August, Leeb issued orders for the blockade of Leningrad in anticipation that the city would soon be abandoned by the Soviets. On September 5, Hitler ordered Hoepner's 4th Panzer Group and an air corps transferred to Army Group Centre effective 15 September, in preparation for Operation Typhoon, the German assault on Moscow. Leeb objected and was given a reprieve in the transfer of his mobile forces, with the view of making one last push towards Leningrad. The 4th Panzer Group was to be the main attacking force, which reached south of the Neva River, where it was faced with strong Soviet counter-attacks. By 24 September, Army Group North halted its advance and transferred the 4th Panzer Group to Army Group Centre.

Sources: en.wikipedia.org

Frequently asked questions

Does this compound occur naturally in the body?

No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.

What does the abbreviation DAC refer to?

DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.

Why do different sources report different half-lives for the same name?

Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.

What is CJC-1295?

It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.

Network